Clinical trial

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

NCT00432172

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Epirubicin Normalized identity: epirubicinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cyclophosphamide Normalized identity: cyclophosphamideView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Exemestane Normalized identity: exemestaneView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Goserelin Normalized identity: goserelinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-04-24

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

EpirubicinDRUG · verified · RxNorm: epirubicin

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

DocetaxelDRUG · verified · RxNorm: docetaxel

ExemestaneDRUG · verified · RxNorm: exemestane

GoserelinDRUG · verified · RxNorm: goserelin

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Spanish Breast Cancer Research Grouplead sponsor

Pfizercollaborator

Mapped research locations

A CoruñaSpain2 MadridSpain1 BarcelonaSpain1 ValenciaSpain1 MálagaSpain1 AlicanteSpain1 CórdobaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00432172 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.